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Abstract
BACKGROUND—Intensive glucose lowering has previously been shown to increase mortality
among persons with advanced type 2 diabetes and a high risk of cardiovascular disease. This
report describes the 5-year outcomes of a mean of 3.7 years of intensive glucose lowering on
mortality and key cardiovascular events.
METHODS—We randomly assigned participants with type 2 diabetes and cardiovascular disease
or additional cardiovascular risk factors to receive intensive therapy (targeting a glycated
hemoglobin level below 6.0%) or standard therapy (targeting a level of 7 to 7.9%). After
termination of the intensive therapy, due to higher mortality in the intensive-therapy group, the
target glycated hemoglobin level was 7 to 7.9% for all participants, who were followed until the
planned end of the trial.
RESULTS—Before the intensive therapy was terminated, the intensive-therapy group did not
differ significantly from the standard-therapy group in the rate of the primary outcome (a
composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes)
(P = 0.13) but had more deaths from any cause (primarily cardiovascular) (hazard ratio, 1.21; 95%
confidence interval [CI], 1.02 to 1.44) and fewer nonfatal myocardial infarctions (hazard ratio,
0.79; 95% CI, 0.66 to 0.95). These trends persisted during the entire follow-up period (hazard ratio
for death, 1.19; 95% CI, 1.03 to 1.38; and hazard ratio for nonfatal myocardial infarction, 0.82;
95% CI, 0.70 to 0.96). After the intensive intervention was terminated, the median glycated
hemoglobin level in the intensive-therapy group rose from 6.4% to 7.2%, and the use of glucose-
lowering medications and rates of severe hypoglycemia and other adverse events were similar in
the two groups.
CONCLUSIONS—As compared with standard therapy, the use of intensive therapy for 3.7 years
to target a glycated hemoglobin level below 6% reduced 5-year nonfatal myocardial infarctions
but increased 5-year mortality. Such a strategy cannot be recommended for high-risk patients with
advanced type 2 diabetes. (Funded by the National Heart, Lung and Blood Institute;
ClinicalTrials.gov number, NCT00000620.)
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Type 2 diabetes mellitus is a strong, independent risk factor for cardiovascular disease and
death,1 and many epidemiologic analyses have identified a progressive relationship between
hyperglycemia and these outcomes.2–5 The Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial was designed to determine whether a strategy of targeting normal
glycated hemoglobin levels (i.e., <6.0%) would reduce the risk of serious cardiovascular
events in middle-aged and elderly people with type 2 diabetes mellitus, glycated hemoglobin
levels of 7.5% or more, and additional cardiovascular risk factors.6 However, on the basis of
a mean of 3.5 years’ worth of data, the independent data and safety monitoring board
recommended termination of the intensive glucose-lowering regimen because of the finding
of higher mortality in the intensive-therapy group. Therefore, we applied the approaches that
were used in the standard control group to participants assigned to the intensive-therapy
group, for up to 17 months of additional follow-up. We report the clinical outcomes at 5
years of follow-up in response to a mean of 3.7 years of an intensive glycemia strategy.
METHODS
STUDY DESIGN
The design and major results of the trial have been published previously.6,7 Briefly, we
recruited male and female volunteers from 77 clinical centers in the United States and
Canada. The participants were 40 to 79 years of age, had type 2 diabetes mellitus and a
glycated hemoglobin level of 7.5% or more, and had previous evidence of cardiovascular
disease or risk factors for cardiovascular disease. Participants were randomly assigned to
receive either intensive glucose-lowering therapy targeting a glycated hemoglobin level of
less than 6.0% or standard glucose-lowering therapy targeting a level of 7 to 7.9%. All
participants received counseling about lifestyle and education about the management of
diabetes. Glucose-lowering drugs were chosen from a common formulary according to the
participant’s studygroup assignment and response to therapy.7 Glycated hemoglobin levels
were audited regularly according to treatment group and study center, and feedback was
provided to facilitate the attainment of the target glycated hemoglobin levels.
TERMINATION OF INTENSIVE REGIMEN AND ASSESSMENT OF OUTCOMES
Recruitment occurred in two phases, from January to June 2001 and from February 2003 to
October 2005. On February 5, 2008, participants were informed of the decision to
discontinue the intensive glucose-lowering regimen, after a mean treatment period of 3.7
years. Participants in the intensive-therapy group subsequently were switched to standard
glycemic therapy, and their target glycated hemoglobin level of less than 6% was changed to
a target level of 7 to 7.9%. Since participants had also been assigned to receive treatment
either to control lipid levels or to lower blood pressure,8,9 they continued to be followed at
least every 4 months until the originally planned end of the trial (June 2009). Thus, data on
clinical outcomes, including the primary outcome (a composite of nonfatal myocardial
infarction, nonfatal stroke, or death from cardiovascular causes) and death from any cause (a
secondary outcome), continued to be collected and adjudicated for an additional 17 months
by a central committee whose members were unaware of study-group assignments.
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The effects of the glycemic intervention during a mean of 3.5 years (until December 10,
2007), which provided the basis for the data and safety monitoring board’s recommendation
to discontinue the intensive regimen, have been reported previously.6 Here we report the
effect of the intervention during an additional 0.2 years (i.e., until February 5, 2008), which
was when participants were informed of the change in approach. We also report on
outcomes that occurred before February 5, 2008, that were not reported to the coordinating
center as of December 10, 2007. Therefore, we used intention-to-treat analyses to report on
the effect of a mean of 3.7 years of an intensive glycemic intervention on cardiovascular
disease, followed by a mean of 1.2 years of standard glycemic therapy. Also reported are the
effects of the glycemic intervention until the transition date and until the end of the overall
trial for both the blood-pressure and lipid trials. The treatment effects of the lipid and blood-
pressure interventions were reported separately.8,9 All primary and secondary outcomes
were adjudicated centrally by two adjudicators who were unaware of treatment-group
assignments, and in addition, deaths were reviewed by two diabetes experts (who were
unaware of treatment-group assignments) to determine whether they were due to
hypoglycemia. The ACCORD trial was sponsored by the National Heart, Lung, and Blood
Institute (NHLBI), and the protocol (available with the full text of this article at NEJM.org)
was approved by an NHLBI review panel and by the ethics committee at each center. All
participants provided written informed consent. All authors vouch for the accuracy and
completeness of the reported data. The donors of medications and devices had no role in the
study design, data accrual and analysis, or manuscript preparation.
STATISTICAL ANALYSIS
All statistical analyses were conducted at the coordinating center with the use of S-Plus
software, version 8.0 (Insightful), or SAS software, version 9.2 (SAS Institute). Baseline
characteristics of the participants were summarized with the use of means, standard
deviations, and percentages. Median glycated hemoglobin levels were calculated monthly
(by calendar month) to show the effect of the switch from intensive therapy to the standard
approach. Exposure to glucose-lowering drugs was summarized as the number of
participants who were prescribed a medication at the last visit before the transition date and
at the trial termination. The incidence of key safety outcomes was expressed as the
percentage of events per follow-up year, taking into account censoring of follow-up data.
Kaplan–Meier estimates were used to calculate the percentage of participants who had an
event during follow-up.
Primary and secondary outcomes were analyzed with the use of Cox proportional-hazards
regression analyses according to the intention-to-treat principle, and between-group
comparisons of the outcomes were performed with the use of hazard ratios and 95%
confidence intervals derived from these models. These analyses were performed for events
occurring from randomization until the date of transition (February 5, 2008) and from
randomization until the final visit (between the beginning of March and the end of June
2009). An additional post hoc analysis was performed for the primary outcome and death
from any cause with the use of data from the post-transition phase only.
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For analyses of outcomes, data from participants without final follow-up data were censored
as of the time of their last completed 4-month visit in both the intensive-therapy and
standard-therapy groups. Data on mortality for participants in the United States who were
not followed for the full follow-up period and who were not known to be deceased were
censored as of the most recent date they were known to be alive or January 1, 2008, on the
basis of the National Death Index.
Silent myocardial infarctions were identified on the basis of electrocardiograms obtained
every 2 years and were considered to have occurred at the midpoint of the dates between the
electrocardiogram showing a new myocardial infarction and the previous electrocardiogram.
Information from electrocardiograms obtained after the transition date were not known to
the data and safety monitoring board or investigators at the time of the transition. Therefore,
new silent myocardial infarctions detected after the transition date that would have been
assigned to the period before transition were deemed to have occurred on the date of
transition; this occurred for 29 participants.
Cox models for the primary outcome contained a term representing study-group assignments
plus terms accounting for the following prespecified stratifying variables: assignment to the
blood-pressure trial or lipid trial; assignment to the intensive blood-pressure intervention in
the blood-pressure trial; assignment to receive fibrate in the lipid trial; the seven clinical
center networks; and the presence or absence of previous cardiovascular disease. For all
secondary outcomes, an a priori decision was made to drop the clinical center networks from
this model, because fewer events were expected than for the primary outcomes. The
consistency of the effect of the study-group assignment on death from any cause and on the
primary outcome in the blood-pressure trial and the lipid trial was assessed with the use of
statistical tests of interactions between the treatment effect and the subgroup within the Cox
models.
Unless otherwise indicated, nominal P values, unadjusted for the multiple tests performed
for this report or for monitoring by the data and safety monitoring board, are reported. Since
we conducted 46 statistical tests of hypotheses related to secondary end points and
subgroups, there was a 91% chance (i.e., 1−[1−0.05]46) that at least one of these tests would
be significant at an alpha level of 0.05, assuming independence between tests.
The effect of the study-group assignment on the primary outcome or mortality after the
transition in participants who had not had a primary outcome and who were alive at the
transition date was explored with the use of Kaplan–Meier curves and Cox regression
models. Further post hoc exploratory analyses to identify factors associated with higher
mortality in the intensive-therapy group have examined baseline characteristics,10 the
achieved glycated hemoglobin level and the rapidity of its decline,11 and hypoglycemic
events.12,13
RESULTS
Baseline characteristics of the participants have been reported previously.6 Table 1 shows
these characteristics before the transition date and at the final visit. Figure 1 in the
Page 4






















Supplementary Appendix (available at NEJM.org) shows the completeness of follow-up in
the two study groups. Median glycated hemoglobin levels before the transition date in the
intensive-therapy and standard-therapy groups were 6.4% and 7.5%, respectively. After the
transition date, therapy was relaxed (i.e., fewer drugs or lower doses were used) for a
particular indication at least as often in the intensive-therapy group as in the standard-
therapy group. For example, at the first post-transition visit, relaxation of therapy was
indicated in 94% of participants in the intensive-therapy group and 69% of those in the
standard-therapy group. At the final visit, median glycated hemoglobin levels were 7.2% in
the intensive-therapy group and 7.6% in the standard-therapy group (Fig. 2 in the
Supplementary Appendix). By the final visit, the numbers of participants who were
receiving metformin, secretagogues, thiazolidinediones, insulin, and combination therapy
with insulin and oral agents were similar in the two groups (Table 1 in the Supplementary
Appendix). Rates of severe hypoglycemia and other adverse events within the two groups
were similar after the transition (Table 2 in the Supplementary Appendix).
Figure 1 shows the incidence of the primary outcome and death from any cause from
randomization until the time of transition, from randomization until the end of the whole
study, and from the transition date until the termination of the trial. Figure 2 shows the effect
of intensive glucose-lowering therapy on all the major outcomes, from randomization until
the end of the active treatment period and until the end of the study. Before the transition,
the incidence of the primary outcome among the participants in the intensive-therapy group
was 2.0% per year, as compared with an incidence of 2.2% per year among the participants
in the standard-therapy group (hazard ratio, 0.90; 95% confidence interval [CI], 0.78 to 1.03;
nominal P = 0.132, and P = 0.134 after adjustment for repeat testing by the data and safety
monitoring board) and remained nonsignificant throughout the entire period of observation
(hazard ratio, 0.91; 95% CI, 0.81 to 1.03; P = 0.12).
The intensive therapy had different effects on two of the key components of this primary
outcome. At the time of the transition, the rate of nonfatal myocardial infarction in the
intensive-therapy group was lower than that in the standard-therapy group (1.08% vs.
1.35%; hazard ratio, 0.79; 95% CI, 0.66 to 0.95; P = 0.01), but the rate of death from
cardiovascular causes was non-significantly higher (0.71% vs. 0.55%; hazard ratio, 1.27%;
95% CI, 0.99 to 1.63; P = 0.07). These divergent effects were retained at the end of the
study, with a rate of nonfatal myocardial infarction in the intensive-therapy group that was
lower than that in the standard-therapy group (1.18 vs. 1.42; hazard ratio, 0.82; 95% CI, 0.70
to 0.96; P = 0.01) and a rate of death from cardiovascular causes that was higher (0.74 vs.
0.57; hazard ratio, 1.29; 95% CI, 1.04 to 1.60; P = 0.02).
Finally, at the time of the transition, there was a 21% higher rate of death from any cause in
the intensive-therapy group than in the standard-therapy group (1.42 vs. 1.16; 95% CI, 1.02
to 1.44; nominal P = 0.030 and P = 0.036 after adjustment for repeat testing by the data and
safety monitoring board) and a 19% higher rate at the end of the study (1.53 vs. 1.27; 95%
CI, 1.03 to 1.38; P = 0.02) (Fig. 1 and 2). The causes of death are listed in Table 2. There
was no clear difference between study groups in any other predefined cardiovascular
outcomes.
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Table 3 lists the annual incidence of the primary and secondary outcomes in the two
treatment groups after the transition date, and Figures 1C and 1F show the corresponding
Kaplan–Meier curves for the primary outcome and death from any cause. Hazard ratios in
the post-transition period were not significantly different from those in the pretransition
period for either the primary outcome (ratio of pretransition to post-transition hazard ratios,
0.95; 95% CI, 0.72 to 1.26; P = 0.72) or death from any cause (ratio of pretransition to post-
transition hazard ratios, 1.06; 95% CI, 0.76 to 1.46; P = 0.74). There was a possible
difference in the effect of the intensive therapy on the pretransition primary outcome among
participants with a baseline glycated hemoglobin level of 8% or less as compared with those
with a level of more than 8% (P = 0.03 for interaction) (Fig. 3 in the Supplementary
Appendix).
A total of 4733 participants were randomly assigned to receive either intensive or standard
therapy to lower their blood pressure, and 5518 participants were randomly assigned to a
statin plus either fenofibrate or placebo for control of low-density lipoprotein cholesterol.
No significant interactions were noted between the glucose-lowering study and the blood-
pressure study for the primary outcome, or between the glucose-lowering study and the lipid
study for either the primary outcome or death from any cause. However, there was evidence
of an interaction between the intensive glucose-lowering group and the intensive blood-
pressure–lowering group with respect to death from any cause both before the transition (P =
0.03 for interaction) and at the end of the trial (P = 0.05 for interaction) (Fig. 4 in the
Supplementary Appendix). Before the transition, this interaction was characterized by a
marginally higher mortality rate in the intensive glucose-lowering group than in the standard
glucose-lowering group among participants also assigned to the intensive blood-pressure–
lowering group (hazard ratio, 1.45; 95% CI, 1.00 to 2.12; P = 0.05) but not among those also
assigned to the standard blood-pressure–lowering group (hazard ratio, 0.78; 95% CI, 0.52 to
1.18; P = 0.24).
DISCUSSION
The ACCORD trial involved persons who had had diabetes for a median of 10 years, with a
glycated hemoglobin level of at least 7.5%, and who had a high risk of cardiovascular
disease. Our findings indicate that in a high-risk population such as this, a mean of 3.7 years
of intensive therapy consisting of multiple glucose-lowering methods to target normal
glycated hemoglobin levels (i.e., below 6.0%) does not result in a significantly lower
number of major cardiovascular events after 5 years than does an approach that uses similar
methods to target levels that are more typically achieved in persons in the United States and
Canada (i.e., 7 to 7.9%). Indeed, the intensive approach led to more deaths. Effects on the
primary outcome were similar during the 3.7-year glucose-lowering period and the entire 5-
year follow-up period; effects on mortality also were similar during the two periods. Similar
effects on the primary outcome and mortality were noted in most of the predefined
subgroups. The nominally positive tests for interaction with respect to the primary outcome
and baseline glycated hemoglobin levels and with respect to death from any cause and the
blood-pressure intervention may well have been due to chance, since a large number of
statistical tests were performed. No inferences can be made about the effect of the
intervention during the post-transition period, because between-group differences during this
Page 6






















period alone are likely to have been driven by between-group differences in the
characteristics of participants who survived and were followed during this period.
Reasons for the higher mortality in the intensive-therapy group during the pretransition
period remain unclear. Because of the equivalent rates of hypoglycemia in the post-
transition period, severe hypoglycemia cannot be implicated. Additional analyses reported
elsewhere12 also do not implicate severe hypoglycemia. According to other analyses, the
degree of reduction in glycated hemoglobin levels cannot be implicated.11 Further analyses
should explore possible explanations, such as the role of various drugs, drug combinations,
or drug interactions; weight gain; the relatively short intervention period (3.7 years); and the
observed interaction between the blood-pressure and glycemia trials with respect to
mortality.
Strengths of our study include the randomized trial design, large sample, wide variety of
clinics, frequent follow-up, high rate of complete follow-up, high rate of adherence to the
study assignment, and adjudication of all events by a central committee that was unaware of
the study-group assignments. The clinical relevance of the results is highlighted by the
following facts: the approach used commonly available drugs, glycemia was managed
within the context of good control of blood pressure and lipid levels, the recruited
participants were representative of many people with diabetes who are currently receiving
care in ambulatory settings, and several organizations have recommended glycemic targets
of 6.5% or lower.
These findings are most applicable to middle-aged and older patients with a long duration of
diabetes, a high risk of cardiovascular disease, and hyperglycemia and should be interpreted
in light of the specific features of the ACCORD trial. For example, the ACCORD trial
excluded people with glycated hemoglobin levels below 7.5%. Moderate heterogeneity with
respect to subgroups predefined by the glycated hemoglobin level at baseline (Fig. 3 in the
Supplementary Appendix) suggests that participants whose glycated hemoglobin level at
baseline was 8% or lower may have had a better response to therapy than participants with
higher glycated hemoglobin levels. Although this hypothesis is clearly not proved by the
ACCORD trial, it is supported by a recent epidemiologic analysis of the cardiovascular
effect of glucose lowering in a cohort of people with type 2 diabetes.14
The ACCORD trial explicitly tested whether targeting a glycated hemoglobin level below
6% by means of a large menu of glucose-lowering agents is superior to targeting a glycated
hemoglobin level of 7 to 7.9%. Therefore, our findings should be interpreted in relation to
these therapies and target glycated hemoglobin levels. Furthermore, targeting normal
glycated hemoglobin levels (i.e., <6.0%) required the use of multiple combinations of
glucose-lowering medications in ways that are not used in standard care. For example, 42%
of participants in the intensive-therapy group were receiving three or more classes of oral
agents, either alone (17%) or in combination with insulin (25%), whereas such combinations
were used in 19% of the participants in the standard-therapy group (Table 1 in the
Supplementary Appendix). Whether these unconventional combinations were responsible
for the results and whether similar findings would have been observed with newer glucose-
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lowering therapies, different drug combinations, or different target glycated hemoglobin
levels is unknown.
Finally, people with newly diagnosed diabetes may have a different response to intensive
glucose-lowering therapy. A large trial involving people with newly diagnosed type 2
diabetes, in which normal glucose levels were targeted and a median glycated hemoglobin
level of 7% (as opposed to 7.9%) was achieved, showed a neutral cardiovascular effect after
10 years but a reduced rate of myocardial infarction and death after 20 years.15
In summary, the results of the ACCORD trial show that in persons who have a high risk of
cardiovascular disease and suboptimally controlled, long-standing diabetes, with good
blood-pressure and lipid control, an intensive therapeutic approach targeting normal
glycated hemoglobin levels with the use of multiple medications is associated with higher
mortality than is a standard approach targeting higher glycated hemoglobin levels. The
higher risk of death from any cause and from cardiovascular causes in the intensive-therapy
group means that a therapeutic approach that targets glycated hemoglobin levels below 6%
cannot be generally recommended in this population. Thus, the results of the ACCORD trial
suggest a lower limit for glycemic targets, achieved with the use of multiple combinations of
currently available approaches.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause
The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or
death from cardiovascular causes. Panels A and D show the incidence rates from
randomization until the time of transition, Panels B and E show the rates from
randomization until the end of the trial, and Panels C and F show the rates for the post-
transition period. Plots for the post-transition period (Panels C and F) are included for
descriptive purposes only; they cannot be used to infer any effect of the intensive therapy in
this period.
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Figure 2. Hazard Ratios for the Prespecified Primary and Secondary Outcomes
The effect of intensive glucose-lowering therapy is shown from randomization until the time
of transition and from randomization until the end of the trial. Squares represent hazard
ratios, and horizontal bars represent 95% confidence intervals. CHF denotes congestive
heart failure.
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Any 283 (5.5) 232 (4.5) 391 (7.6) 327 (6.4)
Cardiovascular disease
  Unexpected or presumed cardiovascular disease 89 (1.7) 78 (1.5) 124 (2.4) 103 (2.0)
  Fatal myocardial infarction 20 (0.4) 12 (0.2) 24 (0.5) 14 (0.3)
  Fatal congestive heart failure 26 (0.5) 20 (0.4) 32 (0.6) 25 (0.5)
  Fatal procedure for cardiovascular disease 11 (0.2) 5 (0.1) 14 (0.3) 7 (0.1)
  Fatal arrhythmia 4 (0.1) 12 (0.2) 6 (0.1) 18 (0.4)
  Fatal procedure for noncardiovascular disease† 1 (<0.1) 4 (0.1) 2 (<0.1) 4 (0.1)
  Fatal stroke 9 (0.2) 12 (0.2) 13 (0.3) 17 (0.3)
  Other cardiovascular disease 8 (0.2) 10 (0.2) 11 (0.2) 10 (0.2)
Cancer 69 (1.3) 70 (1.4) 102 (2.0) 101 (2.0)
Condition other than cancer or cardiovascular disease 57 (1.1) 40 (0.8) 84 (1.6) 60 (1.2)
Undetermined 11 (0.2) 12 (0.2) 12 (0.2) 21 (0.4)
Identified through National Death Index 6 (0.1) 1 (<0.1) 6 (0.1) 1 (<0.1)
*
Data within categories are not mutually exclusive, and persons who were classified as having more than one possible cause of death are listed in
the relevant categories.
†
This condition was a component of the outcome of fatal cardiovascular disease.
























Incident Event Rates after the Transition Date.*
Outcome Intensive Therapy Standard Therapy
no. of
patients (%) % per year
no. of
patients (%) % per year
Primary outcome† 123 (2.8) 2.35 129 (2.9) 2.47
Secondary outcome
  Nonfatal myocardial infarction 80 (1.8) 1.51 87 (2.0) 1.64
  Nonfatal stroke 10 (0.2) 0.18 22 (0.5) 0.40
  Death
    Cardiovascular causes 47 (1.0) 0.84 35 (0.7) 0.62
    Any cause 108 (2.3) 1.92 95 (2.0) 1.67
Primary outcome, revascularization, or hospitalization for heart failure 227 (5.8) 4.97 274 (7.0) 6.04
Fatal or nonfatal myocardial infarction or unstable angina 141 (3.2) 2.74 138 (3.2) 2.70
Fatal or nonfatal stroke 13 (0.3) 0.24 26 (0.6) 0.47
Fatal or nonfatal congestive heart failure 43 (1.0) 0.80 54 (1.2) 0.99
*
Data are for descriptive purposes only and cannot be used to infer any effect of the intervention during the post-transition period alone; therefore,
statistical tests are not included.
†
The primary outcome was a composite of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes.
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